)
Olema Oncology (OLMA) investor relations material
Olema Oncology Stifel 2026 Healthcare Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.OPERA clinical programs
OPERA-01, a 2L/3L monotherapy study, is expected to read out in Q1; the key test is whether phase II results replicate in phase III. Phase II median PFS was 7.3 months in ESR1-mutant and 5.5 months in wild-type patients.
Palazestrant’s proposed differentiators include a 14-day half-life, higher exposure and complete ER antagonism; OPERA-01 separately analyzes ESR1-mutant and wild-type populations.
OPERA-02, a first-line study with KISQALI, is enrolling robustly. Enrollment excludes endocrine-resistant patients with less than 6 months’ response to prior endocrine therapy in advanced disease.
OPERA-02 enrollment may be expanded after review of SERENA-4 control-arm data at San Antonio in early December; added enrollment would modestly extend timing, while readout depends on event rate.
Combination data and pipeline
San Antonio presentations will include mature post-CDK4/6 everolimus-combination data with Kaplan-Meier PFS, tolerability and ESR1-mutant/wild-type analyses.
Atirmociclib combination enrollment is complete; initial tolerability and response-rate data will be presented in a mixed frontline/post-CDK4/6 population, without mature durability data.
The KAT6 inhibitor poster will update monotherapy and show initial breast-cancer fulvestrant-combination tolerability across multiple dose levels; dose selection remains ongoing.
Palazestrant plus KAT6 data are targeted for mid-2027; prostate-cancer enrollment with NUBEQA is expected to start in the near future, with data earliest by late 2027.
Commercial strategy and financing
Success in both OPERA-01 populations could support an oral endocrine option across a broader market; management cited a ~$5B opportunity, including $3B with no competition, versus ~$2B for ESR1-mutant disease.
U.S. launch preparations are underway, with a potential launch around mid-2028 contingent on a positive, fileable OPERA-01 readout; plans include U.S. and ex-U.S. filings and seeking collaborators for launch and ex-U.S. markets.
Cash was $414M at Q3 end, expected to support the launch window conditional on OPERA-01; management cited a favorable cash position and potential non-equity capital options.
- OPERA-01 data in Q1 2027 will test palazestrant across both ESR1 subsets.OLMA
3rd Annual Guggenheim Healthcare Innovation Conference - Clinical spending deepened losses, while cash runway is projected through mid-2028.OLMA
Q3 2026 - Phase III breast cancer trial readout for palazestrant expected Q1 2027; new combo data due next year.OLMA
H.C. Wainwright 28th Annual Global Investment Conference - Palazestrant and KAT6 programs offer strong differentiation and major market potential, with key data ahead.OLMA
Morgan Stanley 24th Annual Global Healthcare Conference - Phase III breast cancer trials for palazestrant target major markets, with key data due in Q1 2027.OLMA
Citigroup’s Biopharma Back to School Summit 2026 - Net loss rose 44% to $63.2M in Q2 2026 as Phase 3 trial enrollment completed and cash reached $461M.OLMA
Q2 2026 - Pivotal trials and new combinations position the pipeline for major advances in breast cancer care.OLMA
Jefferies London Healthcare Conference 2025 - Phase III breast cancer data expected in fall; KAT6 combos and strong cash position support growth.OLMA
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Promising clinical progress and strategic trial updates position the pipeline for significant impact.OLMA
Jefferies Global Healthcare Conference 2026
Next Olema Oncology earnings date
Next Olema Oncology earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)